NCT01145677

Brief Summary

This is a 12-Week, randomized controlled study of topiramate in hospitalized patients with alcoholism

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jun 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2010

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

June 16, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 17, 2010

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

June 23, 2011

Status Verified

June 1, 2010

Enrollment Period

9 months

First QC Date

June 16, 2010

Last Update Submit

June 22, 2011

Conditions

Keywords

Alcohol dependenceAlcoholismTopiramate

Outcome Measures

Primary Outcomes (1)

  • Alcohol drink/day

    Alcohol drink/day assessed by the use of time line follow back

    12 weeks

Secondary Outcomes (1)

  • Common adverse effect

    12 week

Study Arms (1)

Topiramate

EXPERIMENTAL
Drug: Topiramate

Interventions

Topiramate 100-300 mg/day orally twice per day

Also known as: Topamax
Topiramate

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patients hospitalized due to alcohol-related problem
  • DSM-IV-TR alcohol dependence
  • for male: history of alcohol drink \>=35/week, female: history of alcohol drink \>=28/week for at least 1 week during four weeks prior to the admission
  • AUDIT score at least 8
  • mild or no alcohol withdrawal symptom
  • BMI \> 18 kg/m2
  • not pregnant and no plan for pregnancy
  • intention to decrease or stop drinking

You may not qualify if:

  • severe psychiatric and cognitive disorders
  • other substance dependence, except nicotine and caffeine dependence, during 6 months prior to enrollment
  • taking antipsychotics, mood stabilizers, anticonvulsants, opioid analgesics, systemic steroids, carbonic anhydrase inhibitors, hydrochlorthiazide, metformin, pioglitazone, or disulfiram
  • unstable medical condition
  • medical history of narrow angle glaucoma, renal impairment, kidney stones, and seizures
  • moderate to high risk of suicide
  • under legal process
  • plan to receive a formal treatment for alcoholism from other treatment settings
  • pregnancy and nursing woman
  • abnormal laboratory tests, including blood urea nitrogen, creatinine, electrolytes, and fasting blood sugar

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Chiang Mai Drug Dependence Treatment Center

Maerim, Chiang Mai, 50180, Thailand

Location

Maharaj Nakorn Chiang Mai Hospital

Muang, Chiang Mai, 50200, Thailand

Location

Suanprung Psychiatric Hospital

Muang, ChiangMai, 50100, Thailand

Location

Maharaj Nakorn Chiang Mai Hospital

Muang, ChiangMai, 50200, Thailand

Location

MeSH Terms

Conditions

Alcoholism

Interventions

Topiramate

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

FructoseHexosesMonosaccharidesSugarsCarbohydratesKetoses

Study Officials

  • Surinporn Likhitsathian, MD

    Department of Psychiatry, Faculty of Medicine, Chiang Mai University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 16, 2010

First Posted

June 17, 2010

Study Start

June 1, 2010

Primary Completion

March 1, 2011

Study Completion

June 1, 2011

Last Updated

June 23, 2011

Record last verified: 2010-06

Locations